Breast cancer drug sex fatty liver
Conditions
Interventions
Control group:Pressure + polykenyl phosphatidylcholine
Experimental group:Organic selenium + polykenyl phosphatidylcholine
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
Female
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Female breast cancer patients diagnosed with ER(+) and/or PR(+); 2. Diagnosed with fatty liver after receiving endocrine therapy; 3. Karnofsky score >= 60 points; 4. Breast cancer patients aged 35-60 years; 5. The patients and their families were aware of the research protocol and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe heart, liver, lung and kidney damage; 2. Patients with mental illness; 3. Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatty liver improvement rate;Liver controlled attenuation parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood lipids and liver function;Life quality evaluation; | — |
Countries
China
Contacts
Public ContactZhang Qing
Outcome results
None listed